Tvardi Therapeutics (NASDAQ:TVRD) & Planet 13 (OTCMKTS:PLNHF) Head-To-Head Comparison

Planet 13 (OTCMKTS:PLNHF) and Tvardi Therapeutics (NASDAQ:TVRD) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Earnings & Valuation

This table compares Planet 13 and Tvardi Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Planet 13	N/A	N/A	N/A	N/A	N/A
Tvardi Therapeutics	$7.14 million	3.35	-$18.21 million	($2.79)	-0.64

Planet 13 has higher earnings, but lower revenue than Tvardi Therapeutics.

Profitability

This table compares Planet 13 and Tvardi Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Planet 13	N/A	N/A	N/A
Tvardi Therapeutics	N/A	-145.40%	-91.11%

Institutional & Insider Ownership

44.7% of Tvardi Therapeutics shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Planet 13 and Tvardi Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Planet 13	0	0	0	0	0.00
Tvardi Therapeutics	1	1	6	1	2.78

Tvardi Therapeutics has a consensus price target of $18.00, indicating a potential upside of 902.79%. Given Tvardi Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Planet 13.

Summary

Tvardi Therapeutics beats Planet 13 on 7 of the 9 factors compared between the two stocks.

About Planet 13

Planet 13 Holdings Inc., an integrated cannabis company, engages in the cultivation, production, distribution, and marketing of cannabis and cannabis-infused products for medical and retail cannabis markets in Nevada, the United States. It also operates licensed cannabis dispensaries; non-cannabis retail merchandise store and event space; and owns and operates Trece Eatery + Spirits, coffee shop and pizzeria. In addition, the company provides consultation, education, and convenience services. It owns and manufactures chocolates, gummies, sparkling beverages, vapes and concentrates, and flowers under the TRENDI, Leaf & Vine, Dreamland, and HaHa, and Medizin brands. The company is headquartered in Las Vegas, Nevada.

About Tvardi Therapeutics

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.